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Abstract: X-linked inhibitor of apoptosis protein (XIAP) is an emerging crucial therapeutic target
in cancer. We report on the discovery and characterisation of small organic molecules from Piper
genus plants exhibiting XIAP antagonism, namely erioquinol, a quinol substituted in the 4-position
with an alkenyl group and the alkenylphenols eriopodols A–C. Another isolated compound was
originally identified as gibbilimbol B. Erioquinol was the most potent inhibitor of human cancer
cell viability when compared with gibbilimbol B and eriopodol A was listed as intermediate.
Gibbilimbol B and eriopodol A induced apoptosis through mitochondrial permeabilisation and caspase
activation while erioquinol acted on cell fate via caspase-independent/non-apoptotic mechanisms,
likely involving mitochondrial dysfunctions and aberrant generation of reactive oxygen species.
In silico modelling and molecular approaches suggested that all molecules inhibit XIAP by binding
to XIAP-baculoviral IAP repeat domain. This demonstrates a novel aspect of XIAP as a key determinant
of tumour control, at the molecular crossroad of caspase-dependent/independent cell death pathway
and indicates molecular aspects to develop tumour-effective XIAP antagonists.
Keywords: phytochemicals; small organic agents; Piper eriopodon, alkenylphenols; human cancer cells;
cell death; apoptosis; caspase-independent cell death; XIAP antagonists; XIAP-BIR3 domain
1. Introduction
The characterisation of small molecules (whose molecular weight does not exceed 900 Daltons) with
well-defined chemical structures is a good approach to develop new therapeutic agents in proliferative,
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infectious, or neurodegenerative disorders [1–5]. Natural products possess enormous structural
and chemical diversity that cannot be matched by any synthetic libraries of small molecules and continue
to show a great translational potential [6–10]. In some cases, the complex chemical composition
of some natural products has made difficult their isolation, structure elucidation and characterisation,
thus prompting the search of new efficient synthetic pathways. In recent years the interest in the
fundamental understanding of natural products and their engineered variants has been strongly
renewed [6].
The simple active chemical structures of phenolic compounds from plants make them optimal
lead candidates because of their broad biological activity, especially the protective, anti-oxidant
and anti-tumour effects [11–14]. Plants of the genus Piper (Piperaceae family), are a very common
food resource in neotropical forests and are widely used to obtain culinary spices. Piper genus
constitutes one major class of medicinal plants and contains a valuable resource of phenolic bioactive
compounds [15–21]. Among them, piplartine, hydroxychavicol, 4-nerodlidylcatechol and gibbilimbols
A–D displayed potent cytotoxic/anti-tumoural effects in a variety of human cancer cells in vitro
and in vivo [19,22–29].
Apoptosis, a closely regulated programmed cell death mechanism, is an essential process to maintain
tissue homeostasis and its escape it is one of the hallmarks of cancer [30]. Substantial advances have
been made on apoptosis-based anti-cancer therapeutics [31]. The most potent human IAP currently
identified is the X-linked inhibitor of apoptosis protein (XIAP), a 57 kDa protein with three zinc-binding
baculovirus IAP repeat (BIR) domains (BIR 1–3) which may also have actions additional to regulation
of apoptosis [32]. The anti-apoptotic function of XIAP is antagonised by the second mitochondria-derived
activator of caspases or direct IAP binding protein with low pI (Smac/DIABLO), a mitochondria protein
released during apoptosis. The key role of XIAP and its potential clinical relevance is well established
in tumours and several XIAP inhibitors have been developed or discovered as cytotoxic agents [32–43].
Despite different small molecules that inhibit XIAP have been identified and are moving through
the pipeline of clinical development, the need of new ones to refine further therapeutic approaches based
on XIAP antagonism is undeniable in translational research [41].
Herein we wish to report the discovery and chemical/biological characterisation of novel natural
small compounds from Piper genus. Furthermore, a deeper insight into their cell death mechanism
in human cells provides a proof-of-concept study of their pharmaceutical potential as antagonists of XIAP
that may open important insights on XIAP as a suitable turning point for multiple cellular pathways.
2. Results and Discussion
2.1. Structural Identification of New Piper Genus-Derived Compounds
The chemical structures of compounds isolated from leaves of P. eriopodon (Figure 1A) were
identified by interpretation of their corresponding high resolution electrospray ionisation mass
spectrometry (HRESIMS), 1H- and 13C-NMR (nuclear magnetic resonance) spectral data, including
attached proton test (APT), correlated spectroscopy (COSY), heteronuclear multiple quantum coherence
(HMQC) and heteronuclear multiple bond correlation (HMBC) experiments, as well as by comparison
of the spectral data with those reported in the literature.
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alkenyl fragment. The 13C-NMR spectrum showed ten signals, practically the same as the alkenyl 
chain of gibbilimbol B, including the double bond position in C-3’, which was confirmed by 
correlations observed in both COSY and HMBC experiments (Figure 1B). Based on the 13C-NMR 
chemical shifts of the allylic carbons δC 34.6 (C-2’) and δC 32.6 (C-5’), the configuration of the double 
bond for compound 2 was assigned as E [18], by comparison with the 13C-NMR chemical shift of the 
allylic carbons in the E analogue gibbilimbol B (δC 34.6 (C-2’) and δC 32.6 (C-5’)), which differed 
significantly from the chemical shift values reported for the Z analogue climacostol [δC 33.2 (C-1’) 
and δC 27.3 (C-4’)] [44]. Thus, the chemical structure of compound 2 was elucidated as (E)-4-(dec-3’-
enyl)benzene-1,2-diol and it was given the common name of eriopodol A. 
Figure 1. Identification of new Piper genus-derived compounds. (A) Structures of compounds 1–5. (B) 
Key correlated spectroscopy (COSY) (bold) and heteronuclear multiple bond correlation (HMBC) 
(H→C) for compounds 2–5. 
Compound 3 (Figure S3, Tables S1 and S2) was obtained as clear oil and its molecular formula 
was deduced as C16H24O2 from the HRESIMS spectrum, which exhibited a molecular ion peak at m/z 
247.1706 [M-H]- (calcd. 247.1703). The 1H-NMR spectrum for compound 3 showed signals for an 
alkenyl chain and two signals in δH 6.11 (2H, d, J = 9.94 Hz) and 6.81(2H, d, J = 9.96 Hz). The 13C-
NMR spectrum for compound 3 showed signals for an α-β unsaturated carbonyl in δC 185.9, an 
Figure 1. Identificati e Piper genus-derived compounds. (A) Structures of compounds 1–5.
(B) Key correlated spectroscopy (COSY) (bold) and h teronuclear multiple bond correlation (HMBC)
(H→C) for compounds 2–5.
Compound 1 (Figure S1, Tables S1 and S2) was obtained as colorless il identifi d unequivoc lly
as gibbilimbol B ((E)-4-(dec-3′-enyl)phenol) [19].
Compound 2 (Figure S2, Tables S1 and S2) was obtained as pale yellow oil. The molecular formula
for compound 2 was established as C16H24O2 based on the HRESIMS peak at m/z 247.1706 [M-H]−
(calcd. 247.1703). The 1H- NMR spectrum showed clear signals for a 1,2,4-trisubstituted aromatic ring
δH 6.77 (1H, d, J = 7.6 Hz, H-6), 6.71 (1H, s, H-3), 6.60 (1H, d, J = 7.5 Hz, H-5) and an alkenyl fragment.
The 13C-NMR spectrum showed ten signals, practically the same as the alkenyl chain of gibbilimbol B,
including the double bond position in C-3′, which was confirmed by correlations observed in both
COSY and HMBC experiments (Figure 1B). Based on the 13C-NMR chemical shifts of the allylic
carbons δC 34.6 (C-2′) and δC 32.6 (C-5′), the configuration of the double bond for compound 2
was assigned as E [18], by comparison with the 13C-NMR chemical shift of the allylic carbons
in the E analogue gibbilimbol B (δC 34.6 (C-2′) and δC 32.6 (C-5′)), which differed significantly from
the chemical shift values reported for the Z analogue climacostol [δC 33.2 (C-1′) and δC 27.3 (C-4′)] [44].
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Thus, the chemical structure of compound 2 was elucidated as (E)-4-(dec-3′-enyl)benzene-1,2-diol
and it was given the common name of eriopodol A.
Compound 3 (Figure S3, Tables S1 and S2) was obtained as clear oil and its molecular formula
was deduced as C16H24O2 from the HRESIMS spectrum, which exhibited a molecular ion peak
at m/z 247.1706 [M-H]− (calcd. 247.1703). The 1H-NMR spectrum for compound 3 showed signals
for an alkenyl chain and two signals in δH 6.11 (2H, d, J = 9.94 Hz) and 6.81(2H, d, J = 9.96 Hz).
The 13C-NMR spectrum for compound 3 showed signals for an α-β unsaturated carbonyl in δC 185.9,
an oxygenated quaternary carbon in δC 69.6 and ten signals for the typical side chain of the alkenyl
fragment. Based on the correlations observed in COSY and HMBC experiments (Figure 1B), the structure
of 3 was determined as a quinol derivative, substituted in the 4-position with an alkenyl group.
The position and geometry of the double bond of compound 3 was assigned by comparing the chemical
shift values of the allylic carbons δC 32.4 (C-2′) and δC 26.6 (C-5′) as explained above for eriopodol
A. The geometry of compound 3 was determined as Z and its chemical structure was elucidated
as (Z)-4-(dec-3′-enyl)-4-hydroxycyclohexa-2,5-dien-1-one. The common name of erioquinol was
then assigned.
Compound 4 (Figure S4, Tables S1 and S2) was obtained as pale yellow oil. The molecular formula
for compound 4 was confirmed to be C16H24O2 based on the HRESIMS peak at m/z 247.1715 [M-H]−
(calcd. 247.1703). The 1H-NMR and 13C-NMR spectra of compound 4 showed almost the same
chemical shifts as the alkenylphenol gibbilimbol B, but without the unsaturated signal in the 1H-NMR
spectrum. Therefore, the carbons C-3′ and C-4′ showed chemical shifts in δC 59.6 (C-3′)
and δC 58.6 (C-4′), corresponding two oxygenated methines from an epoxide group, which was
confirmed with COSY and HMBC experiments (Figure 1B). The structure of compound 4 was elucidated
as 4-(3′,4′-epoxydecenyl)phenol and the common name of eriopodol B was assigned.
Compound 5 (Figure S5, Tables S1 and S2) was obtained as pale yellow amorphous solid
(m.p. 138.5 ◦C). The molecular formula for compound 5 was established as C18H28O3 based
on the HRESIMS peak at m/z 291.1973 [M-H]− (calcd. 291.1966). The NMR data for compound 5
were very close to those of eriopodol A, although it contains one additional hydroxyl group in the benzene
ring and two additional carbons at the end of the alkenyl chain (Figure 1B). The position and geometry
of the double bound for compound 5 was assigned as explained above. The structure of compound 5 was
elucidated as (E)-5-(dodec-3′-enyl)benzene-1,2,4-triol and the common name of eriopodol C was assigned.
Taken together, phytochemical investigation of leaves from P. eriopodon yielded four new
alkenyl derivatives and one known compound. In particular, erioquinol is a new quinol substituted
in the 4-position with an alkenyl group and eriopodols A-C correspond to new alkenylphenols.
The known isolated compound was originally identified as gibbilimbol B, from the medicinal plant P.
gibbilimbum [19] and, more recently, from P. malacophyllum [21] and P. eriopodon [29]. The simple
chemical structure of alkenylphenols are characterised by hydroxylated benzenes, substituted
by side alkyl chains of different lengths with at least one double bond, generally with E geometry.
Alkenylphenols with different reported biological properties, such as antibacterial, anti-parasitic,
anti-inflammatory and cytotoxic activities, are widely found in the Piper genus [17,19–21,45].
Quinols are 4-hydroxycyclohexa-2,5-dien-1-ones which rarely occur as derivatives of some natural
products [46–48]. An important feature of quinols substituted in the 4-position with aryl groups, is that
they represent a class of potent anti-tumour molecules with activities against colon, renal, and breast
cancer cells [49–51].
2.2. Piper Genus-Derived Compounds Exhibit Cytotoxic Effects
Several recent studies in glioblastoma and breast cancer cells have reported that extracts or active
compounds isolated from Piper genus possess anti-tumoural/pro-apoptotic properties [52–61]. In order
to assess whether the compounds we isolated could be developed further for therapeutic applications,
we tested their cytotoxic action in the human cancer cells, U373 (glioblastoma astrocytoma) and MCF7
(breast adenocarcinoma) cell lines, since they are widely used as suitable in vitro models of cancer
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research. We first examined the effects of gibbilimbol B, eriopodols A–C, and erioquinol on cell viability.
Gibbilimbol B was used as a reference compound of Piper genus derivatives, since its cytotoxic action
has been previously tested in various tumour cells, including MCF7 [19,29]. In our experiments,
cell viability was analysed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay after treatment with previously mentioned compounds at increasing concentrations for 24 h.
As shown in Figure 2, a concentration-dependent inhibition of MTT absorbance was observed
for all compounds with an IC50 (the concentration producing half the maximum inhibition)
ranging from 1.78 to 31.91 µg/mL; the rank order of potencies was: erioquinol > eriopodol A
> eriopodol C > gibbilimbol B > eriopodol B and erioquinol > eriopodol A > eriopodol C/gibbilimbol
B > eriopodol B for U373 and MCF7 cells, respectively (Table 1). Their effects were maximal
(Emax—concentration producing the maximum effect—nearly 100% inhibition) between 10–100 µg/mL.
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eriopodol C, and erioquinol for 24 h before 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
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and erioquinol for 24 h before 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay. Results are expressed by setting the absorbance of the reduced MTT in the respective control
(vehicle-treated) samples, i.e., absence of compounds, as 100%. The data points are representative
of four independent experiments.
Table 1. Inhibitory effects of Piper genus-derived compounds on human cancer cell viability.
Compound IC50 (µg/mL)
U373 Cells MCF7 Cells
Gibbilimbol B 16.79 16.44
Eriopodol A 11.12 10.12
Eriopodol B 31.91 29.36
Eriopodol C 14.30 16.30
Erioquinol 1.78 2.63
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed treating cells for 24 h
in the absence (vehicle) or in the presence of increasing concentrations of Piper genus-derived compounds. The results
have been obtained in four independent experiments.
Eriopodol A and erioquinol were selected for further investigation, as they displayed the most
potent inhibitory effects on cell viability. Gibbilimbol B (available in high quantity) was also included.
When compared with gibbilimbol B [29], the higher cytotoxic effect of eriopodol A and erioquinol (24 h),
was also shown by MTT assays using additional cell lines, like human A549 lung (IC50 of eriopodol A
and erioquinol: 6.12 and 2.65µg/mL, respectively) and PC-3 prostate (IC50 of eriopodol A and erioquinol:
1.84 and 2.21 µg/mL, respectively) cancer cells, further confirming enhanced pharmacological activity
of these new Piper genus derivatives (Figure 3A).
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(B) human umbilical vein endothelial cells (HUVEC)/MCF10 cells were treated with
increasing concentrations of gibbilimbol B, eriopodol A, and erioquinol, for 24 h before
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results are expressed
by setting the absorbance of the reduced MTT in the respective control (vehicle-treated) samples,
i.e., absence of compounds, as 100%. The data points are representative of four independent experiments.
Similar results were obtained in human umbilical vein endothelial cells (HUVEC) (IC50 of 24 h
gibbilimbol B, eriopodol A, and erioquinol: 11.49, 0.99, and 0.36 µg/mL, respectively) and the
non-tumourigenic human breast MCF10 cells (IC50 of 24 h gibbilimbol B, eriopodol A, and erioquinol:
17.11, 4.27, and 1.70 µg/mL, respectively) (Figure 3B). The fact that the potency of the compounds was
even slightly higher in these non-transformed/high proliferating cells suggests that their effects are not
necessarily correlated to the cancerous origin of cells, in agreement with other small molecules we have
recently characterised [62]. On the other hand, many cytotoxic compounds, including chemotherapy
agents, are specifically designed to primarily affect rapidly proliferating cells, and many “normal” cells
are also highly proliferative, such as cells in the bone marrow. The possibility that Piper genus-derived
compounds preferentially affect high proliferating vs. low proliferating cells remains to be elucidated.
We then measured the concentration-dependent inhibition of MTT absorbance at increasing
times of exposure in MCF7 cells, used as reference cell line. Our results indicated that the potency
of gibbilimbol B did not substantially change (IC50-6 h: 20.31 µg/mL; 12 h: 27.36 µg/mL; 24 h: 16.44
µg/mL) while the potency of eriopodol A increased at 24 h (IC50 - 6 h: 31.19 µg/mL; 12 h: 32.75 µg/mL;
24 h: 11.13 µg/mL) (Figure 4). Of interest, the potency of erioquinol was greater than gibbilimbol B
and eriopodol A at each time-point, even increasing over time (IC50-6 h: 14.72 µg/mL; 12 h: 4.25 µg/mL;
24 h: 1.93 µg/mL). These comparative data indicate that erioquinol is the most potent compound with
faster kinetics when compared with gibbilimbol B; eriopodol A has a somewhat intermediate behavior.
Cancers 2019, 11, 1336 7 of 30 
Similar results were obtained in human umbilical vein endothelial cells (HUVEC) (IC50 of 24 h 
gibbilimbol B, eriopodol A, and erioquinol: 11.49, 0.99, and 0.36 μg/mL, respectively) and the non-
tumourigenic human breast MCF10 cells (IC50 of 24 h gibbilimbol B, eriopodol A, and erioquinol: 
17.11, 4.27, and 1.70 μg/mL, respectively) (Figure 3B). The fact that the potency of the compounds 
was even slightly higher in these non-transformed/high proliferating cells suggests that their effects 
are not necessa ily correlated to the cancerous origin f c lls,  agreement with o er small molecules 
we have cently chara terised [62]. On the other hand, a y cy ot xic co pounds, including 
chemotherapy agents, are specifically designed to primarily affect rapidly proliferating cells, and 
many “normal” cells are also highly proliferative, such as cells in the bone marrow. The possibility 
that Piper genus-derived compounds preferentially affect high proliferating vs. low proliferating cells 
remains to be elucidated. 
We then measured the concentration-dependent inhibition of MTT absorbance at increasing 
times of exposure in MCF7 cells, used as reference cell line. Our results indicated that the potency of 
gibbilimbol B did not substantially change (IC50-6 h: 20.31 μg/mL; 12 h: 27.36 μg/mL; 24 h: 16.44 
μg/ L) while the potency of eriopodol A increased at 24 h (IC50 - 6 h: 31.19 μg/mL; 12 h: 32.75 μg/mL; 
24 h: 11.13 μg/mL) (Figur  4). Of interest, the potency of erioquinol was greater than gibbilimbol B 
and eriopodol A at each time-point, even increasing ver time (IC50-6 h: 14.72 μg/mL; 12 h: 4.25 
μg/mL; 24 h: 1.93 μg/mL). These comparative data indicate that erioquinol is the most potent 
compound with faster kinetics when compared with gibbilimbol B; eriopodol A has a somewhat 
intermediate behavior. 
Figure 4. Time-response of Piper genus-derived compounds on cell viability. MCF7 cells were treated 
with increasing concentrations of gibbilimbol B, eriopodol A, and erioquinol for 6, 12, and 24 h before 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results are expressed by 
setting the absorbance of the reduced MTT in the respective control (vehicle-treated) samples, i.e., 
absence of compounds, as 100%. The data points are representative of four independent experiments.  
2.3. Piper Genus-Derived Compounds Induce Cell Death 
MCF7 cells treated for 12 h with gibbilimbol B and eriopodol A (30 μg/mL) showed an inter-
nucleosomal degradation of genomic DNA typical of late apoptotic cells, as determined by a terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (Figure 5A), while DNA 
fragmented cells were few following erioquinol (10 μg/mL) treatment. Bright field microscopy 
demonstrated that cells exposed to increasing concentrations of gibbilimbol B and eriopodol A at 6 h 
(a temporal window sufficient to determine their cytotoxic effects) had morphological hallmarks of 
apoptosis, such as progressive roundness, shrunken cytoplasm and the formation of condensed 
nuclei (Figure 5B). In contrast, cells treated with erioquinol displayed a translucent cytoplasm and no 
overall nuclei condensation. Of interest, 4',6-diamidine-2'-phenylindole dihydrochloride (DAPI) 
staining clearly revealed the nuclei of cells undergoing apoptosis in the presence of gibbilimbol B and 
eriopodol A (30 μg/mL) for 6 h, while erioquinol (10 μg/mL) treatment was associated with the 
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Figure 4. Time-response of Piper genus-derived compounds on cell viability. MCF7 cells were treated
with increasing concentrations of gibbilimbol B, eriopodol A, and erioquinol for 6, 12, and 24 h before
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results are expressed
by setting the absorbance of the reduced MTT in the respective control (vehicle-treated) samples,
i.e., absence of compounds, as 100%. The data points are representative of four independent experiments.
2.3. Piper Genus-Derived Compounds Induce Cell Death
MCF7 cells treated for 12 h with gibbilimbol B and eriopodol A (30 µg/mL) showed
an inter-nucleosomal degradation of genomic DNA typical of late apoptotic cells, as determined
by a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (Figure 5A),
while DNA fragmented cells were few following erioquinol (10 µg/mL) treatment. Bright field
microscopy demonstrated that cells exposed to increasing c centrations of gibbilimbol B and eriopodol
A at 6 h (a temporal window sufficient to determine their cytotoxi effects) had morphological hallmarks
of apoptosis, such as progressive roundness, shrunken cytoplasm and the formation of condensed
nuclei (Figure 5B). In contrast, cells treated with erioquinol displayed a translucent cytoplasm and no
overall nuclei condensation. Of interest, 4’,6-diamidine-2’-phenylindole dihydrochloride (DAPI)
staining clearly revealed the nuclei of cells undergoing apoptosis in the presence of gibbilimbol B
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and eriopodol A (30 µg/mL) for 6 h, while erioquinol (10 µg/mL) treatment was associated with
the appearence of multinucleated cells (Figure 5C). Accordingly, when analysed by flow cytometry
using Annexin V and propidium iodide (PI) staining, MCF7 cells treated with erioquinol showed
a progressive and marked increase of membrane disruption, as shown by early positivity to both
Annexin V and PI staining, while the typical early apoptotic pattern, evidenced as Annexin V+/PI−
was almost undetectable over time (Figure 5D).
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dUTP nick end labeling (TUNEL) staining of MCF7 cells treated for 12 h in the absence (CTRL,
control) and in the presence of gibbilimbol B/eriopodol A (30 µg/mL) or erioquinol (10 µg/mL).
4’,6-diamidine-2’-phenylindole dihydrochloride (DAPI) was used for nuclei detection. Scale bar = 50 µm.
(B) Bright field microscopy of MCF7 cells treated for 6 h in the absence (CTRL) and in the presence
of gibbilimbol B, eriopodol A, or erioquinol at increasing concentrations. Scale bar = 100 µm.
(C) 4’,6-diamidine-2’-phenylindole dihydrochloride (DAPI) staining of MCF7 cells treated for 6 h in the
absence (CTRL) and in the presence of gibbilimbol B/eriopodol A (30 µg/mL) or erioquinol (10 µg/mL).
Scale bar = 10 µm. Lower panels represent enlarged image details. (D) Evaluation by flow cytometry
of Annexin V-fluorescein isothiocyanate(FITC)/propidium iodide (PI) staining in MCF7 cells treated
in the absence (CTRL) and in the presence of 10 µg/mL erioquinol, for 3 and 6 h. Quadrants are drawn,
and relative proportion of labelled cells is indicated. The events shown in the lower left-hand quadrant are
unlabeled cells. Images and data are representative of four independent experiments.
In addition, cells treated with 30 µg/mL gibbilimbol B and eriopodol A displayed activation
of caspase 9 and 7 at 3 h and 6 h, as showed by western blot analysis (Figure 6A,B). On the other
hand, erioquinol (10 µg/mL) treated cells did not display any sign of caspase 7 activity even at later time
point (Figure 6C). These results were confirmed by immunofluorescence experiments. Indeed, a time-
dependent and intensive cleaved-caspase 7 staining was detected in the cytoplasm of MCF7 cells in the
presence of gibbilimbol B and eriopodol A while positive cells were absent following the administration
of erioquinol (Figure 6D). The activation of caspase 7 by 6 h gibbilimbol B and eriopodol A (30 µg/mL) but
not erioquinol (10 µg/mL) was achieved also in U373 cells (Figure 7A). The fact that these cells displayed
apoptotic and non-apoptotic features in the presence of gibbilimbol B/eriopodol A and erioquinol,
respectively (Figure 7B), similarly to what obtained in MCF7 cells, indicate that cell death mechanisms
of the compounds are comparable among cell lines. Accordingly, the activation of caspase 7 by gibbilimbol
B and eriopodol A but not erioquinol was observed also in MCF10 cells (Figure S6A).
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Figure 6. Piper genus-derived compounds induce cell death. Western blot analysis of cleaved-caspase
9 and 7 in MCF7 cells treated for increasing times in the absence (CTRL, control) and in the presence
of (A) gibbilimbol B or (B) eriopodol A. Vinculin was used as internal standard. Right panels:
densitometric analysis expressed as fold change of CTRL. Images and data are representative of three-five
independent experiments. * p < 0.01, ** p < 0.001, and *** p < 0.0001 relative to CTRL. (C) Western blot
analysis of cleaved-caspase 7 in MCF7 cells treated for increasing times in the absence (CTRL)
and in the presence of 10 µg/mL erioquinol. The stain-free gel was used as loading control. Images are
representative of three independent experiments. PC: positive control. (D) Immunofluorescence
imaging of cleaved-caspase 7 (punctate red pattern) in MCF7 cells treated for 3 and 6 h in the absence
(CTRL) and in the presence of gibbilimbol B/eriopodol A (30 µg/mL) or erioquinol (10 µg/mL).
4’,6-diamidine-2’-phenylindole dihydrochloride (DAPI) (blue) and phalloidin (green) were used
for nuclei and cytoskeleton detection, respectively. Images are representative of four independent
experiments. Scale bar = 25 µm.
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Figure 7. Piper genus-derived compounds induce cell death and mitochondrial dysfunction. (A) 
Immunofluorescence (confocal) imaging of cleaved-caspase 7 (punctate red pattern) in U373 cells 
treated for 6 h in the absence (CTRL, control) and in the presence of gibbilimbol B/eriopodol A (30 
μg/mL) or erioquinol (10 μg/mL). 4',6-diamidine-2'-phenylindole dihydrochloride (DAPI) (blue) and 
phalloidin (green) were used for nuclei and cytoskeleton detection, respectively. Scale bar = 25 μm. 
(B) Bright field microscopy (upper panels) and DAPI staining (lower panels) of U373 cells treated for 
6 h in the absence (CTRL) and in the presence of of gibbilimbol B/eriopodol A (30 μg/mL) or erioquinol 
(10 μg/mL). Scale bars = 50 μm (bright field) and 10 μm (DAPI). Lower panels represent enlarged 
image details. (C) Quantitative analysis of tetramethylrhodamine methyl ester (TMRM) fluorescence 
changes over time in MCF7 (left panel) and U373 (righ panel) cells in the absence (CTRL) and in the 
presence of gibbilimbol B/eriopodol A (30 μg/mL) or erioquinol (10 μg/mL). Results are expressed by 
setting TMRM fluorescence in the respective control (vehicle-treated) samples, i.e., absence of 
Figure 7. Piper genus-derived compounds induce cell death and mitochondrial dysfunction.
(A) Im unofluorescence (confocal) imaging of cleaved-caspase 7 (punctate red pat ern) in U373
cells treated for 6 h in the absence (CTRL, control) and in the pres nce of gibbilimbol B/eriopodol A
(30 µg/mL) or erioquinol (10 µg/mL). 4’,6-diamidine-2’-phenylindole dihydrochloride (DAPI) (blue)
and phalloidin (green) were used for nuclei and cytoskeleton detection, respectively. Scale bar = 25 µm.
(B) Bright field microscopy (up er panels) and DAPI staining (lower panels) of U373 cells treated for 6 h
in the absence (CTRL) and in the presence of of gibbilimbol B/eriopodol A (30 µg/mL) or erioquinol
(10 µg/mL). Scale bars = 50 µm (bright field) and 10 µm (DAPI). Lower panels represent enlarged image
details. (C) Quantitative analysis of tetramethylrhoda ine methyl ester (TMRM) fluorescence changes
over time in MCF7 (left panel) and U373 (righ panel) cells in the absence (CTRL) and in the presence
of gibbilimbol B/eriopodol A (30 µg/mL) or erioquinol (10 µg/mL). Results are expressed by setting
TMRM fluorescence in the respective control (vehicle-treated) samples, i.e., absence of compounds, as 1.
*** p < 0.0001 relative to CTRL. Images and data are representative of four independent experiments.
Cancers 2019, 11, 1336 12 of 30
In order to better describe the mechanism behind the activity of the compounds, we investigated
mitochondria functionality with tetramethylrhodamine methyl ester (TMRM), a red fluorescent dye
that is sequestered by active mitochondria. Of note, MCF7 and U373 cells treated for increasing time
with 30 µg/mL gibbilimbol B/eriopodol A or 10 µg/mL erioquinol presented a comparable decrease
in TMRM fluorescence vs. control, with MCF7 cells full responding within 1 h (Figure 7C). This indicates
low mitochondria membrane potential likely associated to the destabilisation of the mitochondrial
membrane systems.
The fact that the three compounds similarly induce mitochondria membrane permeabilisation both
in MCF7 and U373 cells, was further confirmed by the subcellular location of cytochrome c. As shown
in Figure 8A,B, 3 h administration of gibbilimbol B/eriopodol/erioquinol induced an alteration
in the cytochrome c staining pattern from mitochondrial (co-localisation with COX IV, a marker
for mitochondria), to a more cytosolic distribution (presence of many clusters which did not overlap
with COX IV), indicating a release of cytochrome c from the dysfunctional mitochondria.
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(B) U373 cells were treated for 3 h in the absence (CTRL, control) and in the presence of gibbilimbol
B/eriopodol A (30 µg/mL) or erioquinol (10 µg/mL). Cells were then stained for cytochrome c (green)
and the mitochondrial marker COX IV). 4’,6-diamidine-2’-phenylindole dihydrochloride (DAPI) (blue)
was used for nuclei detection. The images are representative of three independent experiments.
Scale bars: 10 µm (MCF7) and 25 µm (U373). Panels on the right represent enlarged image details.
Damaged mitochondria are considered as the main source of reactive oxygen species (ROS) which
play major roles in the fate of cancer cells [63]. Noteworthily, MCF7 and U373 cells staining with
2’-7’dichlorofluorescin diacetate (DCFH-DA), a permeant fluorogenic dye cell reagent that measures
hydroxyl, peroxyl and other ROS activity, revealed that erioquinol effect (10 µg/mL, 6 h) is characterised
by marked accumulation of ROS, which are absent in cells treated with gibbilimbol B and eriopodol
A (30 µg/mL, 6 h) (Figure 9A,B). Together with lack of caspase activation, aberrant ROS production
is another divergence between gibbilimbol B/eriopodol A and erioquinol-induced cell death. In this
respect, erioquinol is likely inducing a robust mitochondrial stress which results in ROS production
and release into the cytoplasm.
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Figure 9. Confocal microscopy for reactive oxygen species (ROS) detection. (A) MCF7 and (B) U373 
cells were treated for 6 h in the absence (CTRL, control) and in the presence of gibbilimbol B/eriopodol 
A (30 μg/mL) or erioquinol (10 μg/mL). Cells were then stained for ROS (2'-7'dichlorofluorescin 
diacetate - DCFH-DA, green). 4',6-diamidine-2'-phenylindole dihydrochloride (DAPI) (blue) and 
phalloidin (red) were used for nuclei and cytoskeleton detection, respectively. The images are 
representative of three independent experiments. Scale bar: 25 μm. 
Finally we confirmed as apoptotic the effect of gibbilimbol B and eriopodol A by inhibiting their 
cytotoxic activity with the pan-caspase inhibitor Z-VAD-(OMe)-FMK. As displayed by MTT assays 
(Figure 10A), the loss of cell viability in MCF7 cells treated with 30 μg/mL gibbilimbol B and 
Figure 9. Confocal microscopy for reactive oxygen species (ROS) detection. (A) MCF7 and (B) U373 cells
were treated for 6 h in the absence (CTRL, control) and in the presence of gibbilimbol B/eriopodol A
(30 µg/mL) or erioquinol (10 µg/mL). Cells were then stained for ROS (2’-7’dichlorofluorescin diacetate
- DCFH-DA, green). 4’,6-diamidine-2’-phenylindole dihydrochloride (DAPI) (blue) and phalloidin (red)
were used for nuclei and cytoskeleton detection, respectively. The images are representative of three
independent experiments. Scale bar: 25 µm.
Finally we confirmed as apoptotic the effect of gibbilimbol B and eriopodol A by inhibiting
their c ic activity wit the pan-c spase inhibitor Z-VAD-(OMe)-FMK. As displayed by MTT
assays (Figure 10A), the loss of cell viability in MCF7 c lls treated with 30 µg/mL gibbilimbol B
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and eriopodol A was significantly inhibited when 50 µM Z-VAD-(OMe)-FMK was simultaneously
added to the 6 h treatment protocol, demonstrating the dependency on caspases of the two
compounds. However, the simultaneous addition of Z-VAD-(OMe)-FMK did not affect the activity
of 10 µg/mL erioquinol. Taken together our data data demonstrate that gibbilimbol B and eriopodol
A effectively induced intrinsic apoptosis triggered by mitochondrial membrane permeabilisation,
release of cytochrome c, an early induction of initiator caspase 9, and a consecutive activation
of effector caspase 7. Erioquinol, although it affects comparably mitochondrial functions, appears to act
in a different manner, i.e., involving mitochondrial ROS release and non-apoptotic/caspase-independent
mechanisms. Caspase-independent cell death was first described to affect mitochondria potential,
and eventually mitochondrial outer membrane permeabilisation [64], although not followed by caspase
activation. Those features resemble the outcome of erioquinol treatment.
Cancers 2019, 11, 1336 14 of 30 
eriopodol A was significantly inhibited when 50 μM Z-VAD-(OMe)-FMK was simultaneously added 
to the 6 h treatment protocol, demonstrating the dependency on caspases of the two compounds. 
However, the simultaneous addition of Z-VAD-(OMe)-FMK did not affect the activity of 10 μg/mL 
erioquinol. Taken together our data data demonstrate that gibbilimbol B and eriopodol A effectively 
induced intrinsic apoptosis triggered by mitochondrial membrane permeabilisation, release of 
cytochrome c, an early induction of initiator caspase 9, and a consecutive activation of effector caspase 
7. Erioquinol, although it affects comparably mitochondrial functions, appears to act in a different 
manner, i.e. involving mitochondrial ROS release and non-apoptotic/caspase-independent 
mechanisms. Caspase-independent cell death was first described to affect mitochondria potential, 
and eventually mitochondrial outer membrane permeabilisation [64], although not followed by 
caspase activation. Those features resemble the outcome of erioquinol treatment. 
Several forms of regulated cell death manifest with a morphology different from apoptosis 
[65,66], and many compounds from nature source can induce non-apoptotic programmed cell death 
in cancer cells [67]. Among them, necroptosis can be partially rescued by the receptor-interacting 
serine-threonine kinase 1 inhibitor necrostatin-1 and ferroptosis by ferrostatin-1, an inhibitor of lipid 
peroxidation. We thus treated MCF7 and U373 cells with increasing concentrations of erioquinol (24 
h) with or without 50 μM necrostatin-1 and 10 μM ferrostatin-1 (2 h pre-treatment). As shown in 
Figure 10B, the concentration-dependent inhibition of MTT absorbance did not change, suggesting 
erioquinol-induced death was independent from necroptosis and ferroptosis, two cell death 
pathways known to be caspase-independent [65,66]. ROS were recently linked to a caspase-
independent form of cell death, which cannot be rescue by necrostatin-1 or ferrostatin-1 treatment, 
and therefore not imputable to either necroptosis or ferroptosis [68]. Treatment with erioquinol might 
lead to a similar cascade of events, although additional work is required to fully characterise the role 
of ROS and the c ll death process induced by this Piper genus-derived compound. 
Figure 10. Piper genus-derived compounds induce caspase-dependent and independent loss of cell 
viability. (A) MCF7 cells were cultured in the absence (CTRL, control) and in the presence of 30 μg/mL 
gibbilimbol B/eriopodol A or 10 μg/mL erioquinol for 6 h, before 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. The pan-caspase inhibitor Z-VAD-(OMe)-FMK (50 μM) 
or its vehicle were used as well. Results are expressed by setting the absorbance of the reduced MTT 
in the CTRL, as 100%. Data are representative of four-twelve independent experiments. *** p < 0.0001 
relative to the respective compound alone, i.e., + Z-VAD vehicle. (B) MCF7 (left panel) and U373 (right 
panel) cells were treated with increasing concentrations of erioquinol for 24 h before MTT assay. 
Erioquinol was administered both in the absence (vehicle) or in the presence of 50 μM necrostatin-1 
and 10 μM ferrostatin-1 (2 h pre-treatment), a necroptosis and ferroptosis inhibitor, respectively. 
Results are expressed by setting the absorbance of the reduced MTT in the control samples (absence 
of erioquinol) as 100%. The data points are representative of four independent experiments. 
  
Figure 10. Piper genus-derived compounds induce caspase-dependent and independent loss of cell viability.
(A) MCF7 cells were cultured in the absence (CTRL, control) and in the presence of 30 µg/mL gibbilimbol
B/eriopodol A or 10µg/mL erioquinol for 6 h, before 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. The pan-caspase inhibitor Z-VAD-(OMe)-FMK (50 µM) or its vehicle were
used as well. Results are expressed by setting the absorbance of the reduced MTT in the CTRL,
as 100%. Data are representative of four-twelve independent experiments. *** p < 0.0001 relative
to the respective compound alone, i.e., + Z-VAD vehicle. (B) MCF7 (left panel) and U373 (right panel)
cells were treated with increasing concentrations of erioquinol for 24 h before MTT assay. Erioquinol
was admi istered both in the absence (vehicle) or in the presence of 50 µM necrostati -1 and 10 µM
ferrostatin-1 (2 h pre-treatment), a n croptosis and ferroptosis inhibit r, respectively. Results are
expressed by setting the ab orbance of the reduced MTT in the control samples (ab ence of erioquinol)
as 100%. The data points ar represe ativ of four independent exp riments.
Several forms of regulated cell death manifest with a morphology different from apoptosis [65,66],
and many compounds from nature source can induce non-apoptotic programmed cell death
in cancer cells [67]. Among them, necroptosis can be partially rescued by the receptor-interacting
serine-threonine kinase 1 inhibitor necrostatin-1 and ferroptosis by ferrostatin-1, an inhibitor
of lipid peroxidation. We thus treated MCF7 and U373 cells with increasing concentrations
of erioquinol (24 h) with or without 50 µM necrostatin-1 and 10 µM ferrostatin-1 (2 h pre-treatment).
As shown in Figure 10B, the concentration-dependent inhibition of MTT absorbance did not change,
suggesting erioquinol-induced death was independent from necroptosis and ferroptosis, two cell death
pathways known to be caspase-independent [65,66]. ROS were recently linked to a caspase-independent
form of cell death, which cannot be rescue by necrostatin-1 or ferrostatin-1 treatment, and therefore not
imputable to either necroptosis or ferroptosis [68]. Treatment with erioquinol might lead to a similar
cascade of events, although additional work is required to fully characterise the role of ROS and the cell
death process induced by this Piper genus-derived compound.
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2.4. XIAP as a Molecular Target of Piper Genus-Derived Compounds
XIAP-mediated inhibition of apoptosis goes through its reversible binding to active caspase-9,
via its BIR3 domain, and caspase-3/7 when stabilised to XIAP-BIR2 domain [69–71]. It has been also
demonstrated that XIAP controls different pathways functionally uncoupled to caspases, leading to the
possibility that XIAP system might control cell death/survival through multiple mechanisms [32,34,72–82].
Embelin, a natural benzoquinone with potential therapeutic interest, has been isolated from
the fruit of the Embelia ribes and discovered through molecular docking analysis of over 8200 molecules
as a potent small molecule XIAP inhibitor that binds to the XIAP-BIR3 domain [83–86]. It should be noted
that embelin displays chemical features similar to those of erioquinol, eriopodol A, and gibbilimbol B [83].
We assessed if erioquinol, eriopodol A, and gibbilimbol B are able to bind to the XIAP-BIR3 domain
in a similar way of embelin. Using molecular docking analysis and molecular dynamics simulations
for embelin and isolated new compounds, it was found the structural basis of the predicted interactions
with the BIR3 domain of XIAP. Figure 11A provides a general view of the docked conformations
obtained for gibbilimbol B, eriopodol A, erioquinol, and embelin. Interestingly, the binding site
for gibbilimbol B, eriopodol A, and erioquinol is the same binding site of embelin and with similar
energy and binding mode. All docked compounds fits in to the P1, P2 and P3 of the P1–P4 pockets
reported for the binding site of the XIAP-BIR3 domain in complex with Smac, the endogenous
antagonist ligand of IAPs [35,87,88].
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Figure 11. X-linked inhibitor of apoptosis protein (XIAP) as a molecular target of Piper genus-derived 
compounds. (A) Molecular docking and (C) dynamics analysis of embelin (orange), erioquinol 
(green), eriopodol A (purple) and gibbilimbol B (blue) in complex with the baculovirus IAP repeat 
(BIR)-3 domain of XIAP (PDB code 5C83). Interacting residues are displayed in wireframe, hydrogen 
bonds are displayed in yellow dot lines and π-π stacking interactions are displayed in blue dot lines. 
(B) Protein-ligand root mean square deviation (RMSD) trajectory of the atomic positions for ligands 
(red, Lig fit Prot) and the receptor (blu, C⍺ positions) BIR-3 domain of XIAP, for the dynamics 
trajectory of 50 ns. 
Figure 11. X-linked inhibitor of apoptosis protein (XIAP) as a molecular target of Piper genus-derived
compounds. (A) olecular docking and (C) dynamics analysis of embelin (orange), erioquinol (green),
eriopodol A (purple) and gibbilimbol B (blue) in complex with the baculovirus IAP repeat (BIR)-3 domain
of XIAP (PDB code 5C83). Interacting residues are displayed in wireframe, hydrogen bonds are displayed
in yellow dot lines and pi-pi stacking interactions are displayed in blue dot lines. (B) Protein-ligand
root mean square deviation (RMSD) trajectory of the atomic positions for ligands (red, Lig fit Prot)
and the receptor (blu, Cα positions) BIR-3 domain of XIAP, for the dynamics trajectory of 50 ns.
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Experimental structures of the XIAP-BIR3 domain in different complexes with embelin, Smac or
Smac mimetics and non-peptidomimetics small molecules, revealed that residues GLY306, THR308,
GLU314, TRP323 and TYR324 are crucial residues involved in the interaction with the BIR3 domain
of XIAP [35,41,86,89]. The results of the docking experiments show a possible binding mode
for gibbilimbol B, eriopodol A, and erioquinol. Accordingly, the phenolic ring of gibbilimbol B
and eriopodol A forms hydrogen bonds with LYS311 and GLU314 (Figure 11A), the quinol ring
of erioquinol forms three hydrogen bonds with THR308, LYS322, and TRP323, while residues GLY306,
LEU307, TRP323, and TYR324 of the XIAP-BIR3 domain forms hydrophobic interactions with the tail
of the alkenyl derivatives.
In addition, molecular dynamics simulations for 50 ns were carried out to assess the stability
of the protein-ligand complexes between the docked compounds and the BIR3 domain of XIAP.
The stability of the modelled complex of alkenyl derivatives and embelin was confirmed during
the period of simulation by little variations in the root mean square deviation (RMSD) trajectory
(Figure 11B). Although some changes were observed in the interacting residues of XIAP BIR-3 domain
after molecular dynamics simulations (Figure S7), the preferred location of the binding mode for all
evaluated ligands were maintained in the pockets P1-P4 of BIR-3 domain of XIAP during the period
of simulation (Figure 11C). Also, the binding mode obtained in the docking and dynamics simulations
for embelin are according to the interactions pattern determined experimentally by NMR studies in the
XIAP-embelin complex, which revealed that TRP323 of the BIR3 domain of XIAP are crucial in the
binding of embelin [86]. These findings strongly suggest the highly stable complex formation between
the BIR-3 domain of XIAP and the alkenyl derivatives.
XIAP is highly expressed in different human tumour cells and cancer specimens from patients
and plays an important role in conferring chemoresistance [33,90]. Because XIAP blocks apoptosis
at the downstream effector phase, where multiple signalling events may converge, it represents
an attractive molecular target for the design of new anti-cancer drugs [32–41,43]. Two broad approaches
have been taken to develop clinical inhibitors of XIAP—antisense oligonucleotides, targeting
the entire protein, and small molecule inhibitors, binding a single domain. Small molecule inhibitors
offer the potential of more rapid inhibition of their target in vivo and more predictable duration
of action [34,41]. Among the small molecule phytochemicals, the XIAP inhibitor embelin exhibited
cytotoxic activity in various human tumoural cells, including breast cancer [83–86,91]. In addition,
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the withaferin-A induced cytotoxicity in human breast cancer cells was associated with suppression
of XIAP protein [92] and berberine was shown to induce apoptosis in tumours, likely through
the inhibition of XIAP [93]. The just mentioned molecular modelling of our new molecules binding
to XIAP-BIR3 domain drove us to examine if they shared a similar activity with already described
XIAP inhibitors. With the aim of understanding the role of XIAP in the cell death phenotype, we first
determined if our cellular model is anyhow affected by XIAP depletion. Using the Lipofectamine
reagent, MCF7 cells were transiently transfected with a XIAP-specific or a scrambled targeting siRNA.
When treated with 50 nM of siRNA for 24 h, the protein levels of XIAP markedly decreased to ca.
45% compared to control siRNA transfected samples (Figure 12A) indicating a partial depletion
of XIAP. In agreement with previous indications [94–96], the outcome in viability of XIAP knockdown
in MCF7 cells, which showed a significant reduction (ca. 40%) in MTT absorbance upon depletion
of XIAP (Figure 12B), led us to the conclusion that MCF7 cells depend on XIAP for survival since
death mechanisms are neutralised by physiological levels of XIAP. We then tried to add clues on
the involvement of XIAP in the cytotoxic effect of Piper genus-derived compounds. As shown
in Figure 12B, XIAP downregulation in MCF7 cells significantly enhanced the toxicity, as measured
by MTT absorbance, of 6 h administration of gibbilimbol B (30 µg/mL), eriopodol A (30 µg/mL)
and erioquinol (10 µg/mL) indicating their combined action with XIAP siRNA in inhibiting cell
viability. Since 100% knockdown was never achieved with siRNA technique (the absence of detectable
XIAP after siRNA transfection, i.e., by XIAP siRNA at 100 nM for 24 h, paralleled the increase
of cleaved-caspase 7 levels and the complete loss of MCF7 cell viability (Figure S6D and data not
shown)), it is reasonable to assume that that the effects of gibbilimbol B/eriopodol A/erioquinol on
the residual XIAP protein in the siRNA-treated cells further induced MCF7 cell death. On the other
hand, similar results (additive effect) would be achieved if the compounds target cytotoxic pathways
other than XIAP. However, although this is not a formal biological evidence, the simplest explanation
of the combined action is a XIAP-mediated mechanism accounting for, at least in part, the cytotoxicity
of our new compounds. Accordingly, the positive effects of gibbilimbol B and eriopodol A on caspase
7 activity robustly increased after XIAP silencing (Figure 12C). Downregulation of XIAP by siRNA is
known to sensitise human breast cancer cells to death mediated by different chemical agents [94,97].
Finally, using real-time PCR and western blot assays to measure XIAP expression, we found that
cell exposure to gibbilimbol B, eriopodol A, and erioquinol at increasing times did not significantly
modify mRNA (Figure 12D) and protein levels (Figure 12E) of XIAP. Overall, our data exclude a role
of gibbilimbol B/eriopodol A/erioquinol on the regulation of XIAP expression but rather are consistent
with the antagonism of XIAP activity through their binding to XIAP-BIR3 domain.
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Figure 12. X-linked inhibitor of apoptosis protein (XIAP) as a molecular target of Piper genus-derived
compounds. (A) Western blot analysis of XIAP in MCF7 cells both untransfected (CTRL, control)
or transfected for 24 h with a XIAP-specific and scrambled targeting (scr) siRNA (50 nM). Lactate
dehydrogenase (LDH) was used as internal standard. Low panel: densitometric analysis expressed as fold
change of scr siRNA. Images and data are representative of three independent experiments. **P < 0.001
relative to scr siRNA. (B) MCF7 cells were transfected for 24 h with a XIAP-specific or scr siRNA (50 nM)
and then cultured in the absence (CTRL) and in the presence of 30 µg/mL gibbilimbol B/eriopodol A
or 10 µg/mL erioquinol for 6 h, before 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. Results are expressed by setting the absorbance of the reduced MTT in the scr siRNA
CTRL, as 100%. Data are representative of three independent experiments. * p < 0.0001 relative to the
respective scr siRNA. (C) Western blot analysis of cleaved-caspase 7 in MCF7 cells transfected for 24 h
with a XIAP-specific or scr siRNA (50 nM) and then cultured in the presence of 30 µg/mL gibbilimbol
B and eriopodol A for 6 h. LDH was used as internal standard. Images are representative of three
independent experiments. (D) Real-time PCR and (E) Western blot analysis of XIAP mRNA and protein
expression, respectively, in MCF7 cells treated for increasing times in the absence (CTRL) and in the
presence of 30 µg/mL gibbilimbol B/eriopodol A or 10 µg/mL erioquinol. β-actin (PCR) and LDH
(Western blot) were used as internal standards. PCR results are expressed as fold change of respective
CTRL, set as 1. Images and data are representative of three independent experiments.
Since escape from apoptosis is one of the preeminent features of cancer, pharmacological interest
in targeting endogenous apoptosis inhibitors, such as B-cell lymphoma (BCL)-2 and IAPs family
members, has been constant [32–43,82,98,99]. The efforts, including clinical trials, directed towards
identifying small molecules inhibitors of the BCL-2 family of proteins and promote apoptosis with
the so-called BH3 mimetics, that mimic the action of certain BH3-only proteins [98], proved the releasing
of “apoptosis brakes” as a winning strategy to induce primary cell death in cancer or to sensitise
tumour to chemotherapy. Differently to BCL-2 family members, IAPs, and in particular XIAP,
have a late role in the apoptotic timeline, and they target already active caspases to prevent cell death.
The structural data surrounding the interaction between the BIR3 domain of XIAP and caspases suggest
that small molecules that bind the BIR3 pocket of XIAP could mimic the action of Smac and inhibit
the interaction between XIAP and caspase [34,41]. Interestingly its multi-domain structure makes XIAP
a component of multiple cellular pathways, not only the ones leading to apoptosis. XIAP versatility
has been highlighted in inflammation and inflammatory cell death, such as necroptosis [32,79–82].
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Even though these aspects are yet to be completely elucidated, we suggest here - in addition to the
widely described activity of XIAP inhibitors in apoptosis induction (gibbilimbol B and eriopodol A)
—an interesting example of how the pharmacological targeting of XIAP-BIR3 domain can go beyond
the simple induction of apoptosis—and extends its influence in modulating cell death signalling
events other than caspase-activation (erioquinol). The relevance of non-apoptotic cell death in cancer
treatment has recently gained interest as a means to simultaneously targetting tumours and enhancing
the inflammatory response [100]; XIAP, in this context, is an interesting crossroad of pathways involved
in both cell death and inflammation.
3. Materials and Methods
3.1. Extraction and Isolation of Natural Compounds
P. eriopodon was collected in Fusagasuga, in the Department of Cundinamarca (Colombia).
The plant material was identified by Dr. Adolfo Jara Muñoz at Herbario Nacional Colombiano
and a voucher specimen (COL516757) was deposited at the Instituto de Ciencias Naturales, Universidad
Nacional de Colombia.
Dried and powdered leaves of P. eriopodon (1.14 Kg) were extracted exhaustively with ethanol
96% (3 × 5L) at room temperature. After filtration, the solvent was evaporated under reduced
pressure, to yield 103.6 g of crude extract. The crude extract (100.0 g) was subjected to silica gel flash
chromatography and eluted with a step gradient of toluene/ethyl acetate (0:100, 20:80, 40:60, 60:40,
80:20 and 0:100 (V/V)) to afford eight fractions. Fraction 1 (34.2 g) was chromatographed over silica
gel, eluting with a mixture of a three-phase n-hexane/dichloromethane/ethyl acetate (25:70:5) solvent
system to afford ten fractions (A to J). Fraction E (10.0 g) was chromatographed over Sephadex LH-20
(4.5 × 45 cm, n-hexane/chloroform/methanol, 2:2:1) to give six fractions (E1 to E6). In agreement with
a previous report [29], compound 1 (7.93 g) was obtained from fraction E3, after column chromatography
on Sephadex LH-20 (4.5 × 30 cm, n-hexane/acetone/methanol, 2:2:1). Fraction E4 (974.6 mg) was
submitted to column chromatography on Sephadex LH-20 (4.0 × 20 cm, n-hexane/acetone/methanol,
2:2:1) to yield six fractions (E4.1 to E4.6). Compound 3 (33.2 mg) was obtained from fraction
E4.4 (378.8 mg) through Sephadex LH-20 (2.0 × 25 cm, n-hexane/acetone/methanol, 2:2:1) and silica
gel column chromatography eluted with n-hexane/acetone 8:2. Fraction E5 (2.19 g) was subjected
to column chromatography on silica gel using a mixture of toluene/ethyl acetate (9:1) to afford ten
fractions (E5.1 to E5.10). Fraction E5.3 (153.2 mg) was purified by flash chromatography to yield
compound 4 (20.0 mg).
Fraction 2 (8.0 g) was submitted to silica gel column chromatography eluted with n-hexane/ethyl
acetate 8:2, yielding seven fractions (K–Q). Fraction Q was subjected to flash chromatography eluted
with dichloromethane/acetone (7:3) to yield six fractions (Q1–Q6). Fraction Q3 (1.44 g) was subjected
to column chromatography over Sephadex LH-20 (4.0 x 20 cm, hexane/acetone/methanol, 2:2:1) to afford
six fractions (Q3.1 to Q3.6). Fraction Q3.4 (239.4 mg) was chromatographed over Sephadex LH-20
(4.0 × 20 cm, hexane/chloroform/methanol, 2:2:1) and then purified by silica gel column chromatography
eluted with n-hexane/acetone (7:3) to yield compound 5 (4.0 mg). Fraction Q6 (570.5 mg) was subjected
to flash chromatography eluted with n-hexane/acetone 7:3 to afford seven fractions (Q6.1–Q6.7).
Compound 2 (166.0 mg) was obtained from fraction Q6.1.
3.2. General Chemical Methods
Flash chromatography was carried out with silica gel (230–400 mesh; Merck, Darmastadt, Germany),
column chromatography was performed using silica gel (70–230 mesh; Merck) and Shepadex® LH20
(Sigma-Aldrich, St. Louis, MO, USA), analytical thin layer chromatography was performed using
precoated silica gel plates 60 F254 (0.25 mm, Merck). 1H and 13C NMR 1D and 2D (COSY, HMQC and
HMBC) spectra, were recorded on an Avance 400 spectrometer (Bruker, Millerica, MA, USA) at 400 MHz
for 1H and 100 MHz for 13C using the solvent peaks as internal references, the spectra were recorded
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in CDCl3 and MeOD (Merck). High-resolution mass data were collected on an Accurate-Mass
quadrupole Time-of-Flight (q-TOF) (Agilent Technologies, Santa Clara, CA, USA) mass spectrometer,
ESI negative mode, Nebuliser 50 (psi), Gas Flow 10 L/min, Gas Temp 350 ◦C. Fragmentor 175 V,
Skimmer 75 V, Vpp 750 V.
3.3. Cell Culture and Chemicals
Human U373 glioma, MCF7 breast cancer, A549 lung cancer and PC-3 prostate cancer cells
were grown in Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 10% foetal bovine
serum, 2 mM glutamine, 100 U/mL penicillin/streptomycin, at 37 ◦C in a humidified atmosphere
containing 5% CO2 (logarithmic growth phase, routine passages every 3 days). The human breast
epithelial cell line MCF10 was cultured in DMEM/F12 Ham’s Mixture supplemented with 5% horse
serum, epithelial growth factor 20 ng/mL, insulin 10 µg/mL, hydrocortisone 0.5 mg/mL, cholera toxin
100 ng/mL, and 100 U/mL penicillin/streptomycin. HUVEC were grown in EGM-2 Endothelial Cell
Growth Medium-2 BulletKit (Lonza, Basel, Switzerland), according to the manufacturer’s protocol.
Foetal bovine serum, horse serum, glutamine and penicillin/streptomycin were obtained from
Euroclone (Milano, Italy). TMRM was purchased from ThermoFisher Scientific (Waltham, MA, USA)
while necrostatin-1 and ferrostatin-1 were obtained from Santa Cruz Biotechnology (Dallas, TX, USA).
Where not indicated, the reagents were purchased from Sigma-Aldrich.
3.4. MTT Assay
U373, MCF7, A549, PC-3, HUVEC, and MCF10 cell viability was determined by MTT assay
using published protocols [101–105]. MTT absorbance was quantified spectrophotometrically using
a Glomax Multi Detection System microplate reader (Promega, Milano, Italy).
3.5. TUNEL Assay
Using published protocols [106,107], MCF7 or U373 cells cultured in 120-mm coverslips were
fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (PB), pH 7.4, for 10 min. The TUNEL method
(DeadEnd Fluorometric TUNEL System, Promega) was used to assay apoptosis, according to the
manufacturer’s protocol. DAPI (nuclei detection) staining was also performed.
3.6. Immunofluorescence Microscopy Analysis
Using published protocols [106,108], MCF7 or U373 cells cultured in 120-mm coverslips were
fixed in 4% paraformaldehyde in 0.1 M PB, pH 7.4, for 10 min. Cells were pre-incubated for 1 h
min with 5% of normal goat serum (Life Technologies, Monza, Italy) in 0.1 M PB (pH 7.4) containing
0.1% Triton X-100, before overnight incubation with the rabbit monoclonal anti-cleaved caspase
7 (Cell Signaling Technology, Danvers, MA, USA). In double-label immunofluorescence experiments,
the mouse monoclonal anti-cytochrome c primary antibody (Cell Signaling Technology) was used
in conjunction with the rabbit monoclonal primary antibody directed to COX IV (Cell Signaling
Technology). For fluorescence detection, coverslips were stained with the appropriate Alexa Fluor
secondary antibodies (Life Technologies) and mounted on glass slides in a ProLong Gold Antifade
Mountant (Life Technologies). DAPI and/or fluorescein phalloidin (cytoskeleton detection) staining
was also used. Cells were analysed with a DMI4000 B automated inverted microscope equipped with
a DCF310 digital camera (Leica Microsystems, Wetzlar, Germany). When indicated, confocal imaging
was performed with a TCS SP8 System (Leica Microsystems). Image acquisitions were controlled
by the Leica Application Suite X.
3.7. Annexin V Staining
MCF7 cells were incubated with 5 µg/mL Annexin V-fluorescein isothiocyanate (FITC) to assess
the phosphatidylserine exposure on the outer leaflet of the plasma membrane, and 5 µg/mL PI
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(DNA-binding probe) to exclude necrotic cells in binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM
CaCl2) [109]. Cell staining was analysed by Gallios Flow Cytometer (Beckman-Coulter, Brea, CA, USA)
and the software FCS Express 4 (De Novo System, Portland, OR, USA).
3.8. Western Blotting
Using published protocols [107,110,111], MCF7 and MCF10 cells were homogenised in RIPA
lysis buffer, supplemented with a cocktail of protease inhibitors (cOmplete; Roche Diagnostics,
Milano, Italy). Equal amounts of proteins were separated by 4–20% SDS-polyacrylamide gel
electrophoresis (Criterion TGX Stain-free precast gels and Criterion Cell system; Bio-Rad, Hercules,
CA, USA) and transferred onto nitrocellulose membrane using a Bio-Rad Trans-Blot Turbo System.
When indicated, the membranes were probed using the rabbit monoclonal anti-cleaved caspase
7 and anti-XIAP (Cell Signaling Technology) primary antibodies. After the incubation with the
appropriate horseradish-peroxidase-conjugated secondary antibody (Cell Signaling Technology),
bands were visualised using the Clarity Western ECL substrate with a ChemiDoc MP imaging system
(Bio-Rad). To monitor for potential artefacts in loading and transfer among samples in different lanes,
the blots were routinely treated with the Restore Western Blot Stripping Buffer (ThermoFisher Scientific)
and re-probed with the goat anti-Lactate dehydrogenase (LDH)-A (Santa Cruz Biotechnology) and the
mouse anti-vinculin primary antibodies. The stain-free gel was used as loading control as well.
When appropriated, bands were quantified for densitometry using the Bio-Rad Image Lab software.
3.9. Mitochondrial Membrane Potential Analysis
Using published protocols [112], mitochondria of MCF7 and U373 cells were labeled using TMRM,
a voltage-sensitive cationic lipophilic dye, partitioning and accumulating in the mitochondrial matrix
based upon the Nernst equation. After treatments, cells were trypsinised, counted and incubated
with 100 nM TMRM for 30 min at 37 ◦C. Fluorescence was measured by using a Glomax Multi
Detection System microplate reader (Promega), excitation wavelength: 525 nm; emission wavelength:
580–640 nm). After background subtraction, the data were normalised on cell number.
3.10. Measurement of ROS
MCF7 or U373 cells cultured in 120-mm coverslips were exposed to 30 µM DCFH-DA (0.1 M PB,
pH 7.4) and fixed in 4% paraformaldehyde for 20 min. For fluorescence detection, coverslips were
mounted on glass slides and observed with a laser-scanning confocal microscope (TCS SP8 System
and Application suite X, Leica Microsystems). DAPI and fluorescein phalloidin (nuclei and cytoskeleton
detection, respectively) staining was also used.
3.11. Molecular Modeling
AutoDock4 was used to carry out the molecular docking. The Protein Data Bank crystallographic
structure PDB 5C83 was considered as receptor model [87]. The preparation of the macromolecule
was made with PyMOL (version 2.0, PyMol Molecular Graphics, Schrodinger, New York, NY, USA)
System) and XIAP-BIR3 domain was selected as receptor [113]. Energy maps was established with
Autogrid4 involving all atom types. After 25 million of energy evaluations in the binding pocket
and using a grid of 50 × 50 × 50 points, all conformations of the ligand were clustered according to the
energy and conformations. The docking results were visualised using the computational program
Maestro 11.6. The molecular dynamics simulations were carried out with Desmond simulation package
of Maestro (Desmond Molecular Dynamics System; D. E. Shaw Research, New York, NY, USA, 2016)
using the OPLS 2005 force field parameters. A solvated system (TIP3P) and a predefined model
for electrically neutral system (physiological concentrations of monovalent ions, NaCl 0.15 M) were
used in an orthorhombic box and maintained at constant temperature of 300 K for all simulations.
The dynamics simulations were analysed using the Simulation Interaction Diagram tool of Desmond
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package, monitoring the behaviour and stability of simulations by RMSD of the ligand and protein
atom positions in time.
3.12. RNA Interference
Gene silencing of XIAP in MCF7 cells was performed as previously published [106]. Briefly, according
to the manufacturer’s protocol, iBONI siRNA Pool (Riboxx, Radebeul, Germany) targeting human XIAP
were mixed to Lipofectamine RNAiMax transfection reagent (Life Technologies). iBONI siRNA Pool
negative control (Riboxx) (scrambled targeting siRNAs) was also used. The mix was added to cultured
MCF7 cells at a siRNA concentration of 50 nM for 24 h.
3.13. Real-Time PCR
The analysis of mRNA expression was performed as previously described [106,114,115].
Briefly, total RNA from MCF7 cells was extracted with the High Pure RNA Isolation Kit
(Roche Applied Science, Mannheim, Germany), according to the manufacturer’s protocol.
First-strand cDNA was generated from 1 µg of total RNA using iScript Reverse Transcription
Supermix (Bio-Rad). Primer pairs (Eurofins Genomics, Milano, Italy) for XIAP (NM_001167;
forward ACCGTGCGGTGCTTTAGTT, reverse TGCGTGGCACTATTTTCAAGATA) and β-actin
(NM_001101; forward ATAGCACAGCCTGGATAGCAACGTAC, reverse CACCTTCTACAAT
GAGCTGCGTGTG) were designed to hybridise to unique regions of the appropriate gene sequence.
PCR was performed using SsoAdvanced Universal SYBR Green Supermix and the CFX96 Touch
Real-Time PCR Detection System (Bio-Rad). The fold change was determined relative to the selected
control sample after normalising to β-actin (internal standard) by the formula 2−∆∆CT.
3.14. Statistics
Statistical significance of raw data between the groups in each experiment was evaluated
using unpaired Student’s t-test (single comparisons) or one-way ANOVA followed by the
Newman-Keuls post-test (multiple comparisons). The IC50 and Emax concentration were determined
by non-linear regression curve analysis of the concentration-effect responses. Potency values
among concentration-response curves were compared with the F-test. Data belonging from different
experiments were represented and averaged in the same graph. The GraphPad Prism software package
(GraphPad Software, San Diego, CA, USA) was used. The results were expressed as means ± standard
error of mean (SEM) of the indicated n values.
4. Conclusions
This study adds to the renewed biological interest in natural derived compounds, by presenting
a chemical and biological characterisation of new small organic molecules derived from Piper
genus plants. Following a recent preliminary report of gibbilimbol B as cytotoxic in breast cancer
cell lines, we explored this observation by comparing it to similarly structured new molecules.
Erioquinol that appeared to be the most potent compound versus gibbilimbol B and eriopodol
A was listed as an intermediate. A more detailed investigation of the biological mechanism
behind these molecules’ activity in shaping cell viability revealed induction of caspase-dependent
apoptosis following exposure of tumour cells to gibbilimbol B and eriopodol A and, interestingly,
display of caspase-independent/non-apoptotic features in cell treated with erioquinol. In silico
modelling and molecular approaches gave us a first preliminary insight into the molecular target
of Piper genus compounds, the anti-apoptotic protein XIAP (Figure 13). Of note, an already identified
XIAP inhibitor shared structural and binding similarities with them. The appeal of XIAP as a therapeutic
target in cancer is not restricted to inhibition of apoptosis, but comprehends the regulation of other
cellular physiological aspects, such as control of caspase-independent cell death. The molecular
signature behind our observation opens important implications to further dissect the role of XIAP
and for the development of novel XIAP antagonists for cancer treatment.
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Escape of both intrinsic and extrinsic apoptosis is a co mon feature of cancer cells. (A) This hallmark
is often carried out by overexpressing anti-apoptotic proteins, such as X-linked inhibitor of apoptosis
protein (XIAP), hich re e ts t e execution of apoptosis by binding of its baculovirus IAP repeat (BIR)
3 domain to alre dy active initiato caspase 9. In order to counteract is resistance to cell death,
several cancer pharm cological therapies have the a m of removing the ‘molecular brakes’ to apop osis
nsi ising cancer cell to undergo loss of viability. The ap oach we described includes the use
of three compounds from Piper genus plants which were predicted to bi XIAP-BIR3 domain.
(B) Two of the compounds (gibbilimbol B and eriopodol A) were shown to induce a classi al
pro-apoptotic response, i cluding mitoch ndrial outer membr ne polarisation, release of cytochrome c,
and subsequent activation of both initiator and effector caspases. (C) Despites triggering a similar
response at the mitochondria level, erioquinol does not act through the apoptotic machinery,
and results in a caspase-independent cell death characterised by cytoplasmic reactive oxygen species
(ROS) accumulation.
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Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/9/1336/s1,
Figure S1: NMR spectroscopy (400 MHz, CDCl3) and HRESIMS of compound 1, Figure S2: NMR spectroscopy
(400 MHz, CDCl3) and HRESIMS of compound 2, Figure S3: NMR spectroscopy (400 MHz, CDCl3)
and HRESIMS of compound 3, Figure S4: NMR spectroscopy (400 MHz, CDCl3) and HRESIMS of compound 4,
Figure S5: NMR spectroscopy (400 MHz, CDCl3) and HRESIMS of compound 5, Figure S6: Western blot,
Figure S7: Protein-ligand interactions fraction for evaluated ligands and X-linked inhibitor of apoptosis protein
(XIAP) baculovirus IAP repeat (BIR)-3 domain during the molecular dynamics trajectory of 50 ns, Table S1: 1H NMR
(400 MHz) data for compounds 1–4 in CDCl3 and compound 5 in MeOD, Table S2: 13C NMR (100 MHz) data
for compounds 1–4 in CDCl3 and compound 5 in MeOD.
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